Eli Lilly

Novo Nordisk touts 'superior' weight loss results in study of high-dose Wegovy
Fierce Pharma
Fri, 01/17/25 - 11:34 am
Novo Nordisk
obesity
semaglutide
Wegovy
Eli Lilly
Zepbound
clinical trials
JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson
BioPharma Dive
Fri, 01/17/25 - 11:30 am
JPMHC 2025
AbbVie
Eli Lilly
Lilly's Omvoh scores second IBD win with FDA nod in Crohn's
First Word Pharma
Wed, 01/15/25 - 11:50 pm
Eli Lilly
Omvoh
IBD
FDA
Crohn's Disease
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
CNBC
Tue, 01/14/25 - 11:07 am
Eli Lilly
earnings
Lilly pads cancer drug pipeline with Scorpion deal
BioPharma Dive
Mon, 01/13/25 - 11:00 am
Eli Lilly
Scorpion Therapeutics
STX-678
cancer
5 questions facing pharma in 2025
BioPharma Dive
Fri, 01/10/25 - 11:47 am
Donald Trump
obesity
Novo Nordisk
Eli Lilly
vaccines
pharma stocks
regulatory
immunology
Eli Lilly pushes into pulmonary fibrosis with $99M deal for Mediar's midphase prospect
Fierce Biotech
Fri, 01/10/25 - 11:39 am
Eli Lilly
idiopathic pulmonary fibrosis
IPF
Mediar Therapeutics
Alzheimer’s disease market expected to reach $19.3bn across the 8MM by 2033
Clinical Trials Arena
Fri, 01/10/25 - 11:18 am
Alzheimer's disease
Eisai
Biogen
Eli Lilly
Alzheon
Lilly crafts deal for up to 5 new ALS antibodies with UK biotech Alchemab
Fierce Biotech
Thu, 01/9/25 - 11:18 am
Eli Lilly
ALS
Alchemab Therapeutics
Launches from Novo, Lilly top Clarivate's annual 'Drugs to Watch' list
Fierce Pharma
Wed, 01/8/25 - 11:20 pm
Novo Nordisk
Awiqli
insulin
CagriSema
Eli Lilly
Ebglyss
Medicare can now cover Eli Lilly’s Zepbound for sleep apnea, Health Department agency says
CNBC
Wed, 01/8/25 - 11:07 pm
Eli Lilly
Zepbound
Medicare
sleep apnea
3 trial readouts that could shake up the obesity market this year
Pharma Voice
Wed, 01/8/25 - 11:15 am
obesity
weight loss
Metsera
MET-097i
Skye Bioscience
nimacimab
Eli Lilly
orforglipron
clinical trials
Lilly asks to join GLP-1 compounding lawsuit
BioSpace
Fri, 01/3/25 - 10:47 am
Eli Lilly
FDA
legal
compounded drugs
GLP-1 agonist
Use of diabetes and anti-obesity drugs surges nationwide
Axios
Fri, 01/3/25 - 10:07 am
obesity
diabetes
Eli Lilly
Novo Nordisk
Ozempic
Wegovy
Mounjaro
Zepbound
GLP-1 agonist
10 clinical trials to watch in the first half of 2025
BioPharma Dive
Thu, 01/2/25 - 11:42 am
clinical trials
Eli Lilly
cardiovascular disease
Arvinas
protein degradation
Vera Therapeutics
IgA nephropathy
Novarts
pelacarsen
Entyvio
IBD
Novo Nordisk
Alzheimer's disease
Beam Therapeutics
sickle cell disease
COMPASS Pathways
psychedelics
Moderna Therapeutics
Verve Therapeutics
high cholesterol
Lilly’s Obesity Drug Zepbound To Be Key 2025 Health Cost Driver
Forbes
Wed, 01/1/25 - 10:49 pm
Eli Lilly
Zepbound
insurance
Zepbound, Mounjaro shortages are resolved, FDA confirms
BioPharma Dive
Thu, 12/19/24 - 09:36 pm
FDA
Eli Lilly
Zepbound
Mounjaro
drug shortages
Big Pharma’s new DTC play: partnering with digital health providers
Pharma Voice
Wed, 12/18/24 - 11:17 am
digital health
Big Pharma
DTC
Ro
LillyDirect
telehealth
Eli Lilly
A new GLP-1 opportunity for pharma: Supporting patients’ emotional barriers to weight loss
Pharmaphorum
Wed, 12/18/24 - 11:14 am
patients
GLP-1 agonists
obesity
weight loss
Novo Nordisk
Eli Lilly
UK's private obesity drug market chooses Lilly's Mounjaro over Wegovy
Yahoo/Reuters
Fri, 12/13/24 - 11:43 am
Eli Lilly
Mounjaro
Novo Nordisk
Wegovy
UK
obesity

Pages